2023 World Conference on Lung Cancer (Posters)-EP11.03. Molecular Characterization and Prognosis of Patients with KRAS Mutant Non-small Cell Lung Cancer

EP11.03. Molecular Characterization and Prognosis of Patients with KRAS Mutant Non-small Cell Lung Cancer - PDF(Slides)

Pdf Summary

A study was conducted to characterize the molecular features and prognosis of patients with KRAS mutant non-small cell lung cancer (NSCLC). The study included 49 patients with KRAS mutations out of a total of 222 patients analyzed. The most common KRAS mutation subtypes were G12C, and the most frequent co-mutations were TP53 and CDKN2A. The study found that patients with KRAS-mutant NSCLC had different prognosis and response to immunotherapy. <br /><br />Patients with early-stage disease (stage I and II) underwent surgery, and some patients with stage IIIA also underwent surgery. However, a proportion of these patients experienced disease relapse during follow-up. The median relapse-free survival was 28 months. For patients with advanced disease (stage IV and those with relapse or progression), the majority received chemoimmunotherapy, and some received chemotherapy, immunotherapy, palliative care, or local treatment of the recurrence.<br /><br />The study found a high response rate and a long progression-free survival (PFS) in KRAS-mutant patients treated with chemoimmunotherapy or immunotherapy. The majority of patients achieved a partial response after first-line treatment. The median PFS for patients who received first-line treatment was 16.8 months, and the median overall survival (OS) for all patients with advanced disease was 9.9 months.<br /><br />The findings of this study suggest that KRAS-mutant NSCLC patients may benefit from chemoimmunotherapy or immunotherapy. However, further prospective studies are needed to confirm these findings and draw definitive conclusions. The study provides valuable insights into the molecular characteristics and prognosis of patients with KRAS mutant NSCLC, which can help guide treatment decisions and improve patient outcomes.

Asset Subtitle

Laura Gutiérrez Sainz

Meta Tag

Speaker Laura Gutiérrez Sainz

Topic Metastatic NSCLC: Immunotherapy - Retrospective

Keywords

KRAS mutant

NSCLC

mutations

co-mutations

immunotherapy

relapse-free survival

chemoimmunotherapy

response rate

prospective studies

molecular characteristics